RHOA and atrial fibrillation: The mechanism behind the prohibition of RhoA for HSF1 to bind to the HSE needs further investigation, but this pathway opens novel insights in potential druggable targets within the RhoA pathway, which may increase cardioprotective HSP levels in AF [38].